Barclays and UBS raised price targets for Exelixis stock, noting that AI stocks are benefiting from Trump-era tariffs.
1 report, 1 independent
Updated Jul 23
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Barclays and UBS raised price targets for Exelixis stock, noting that AI stocks are benefiting from Trump-era tariffs.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Exelixis
American biotechnology company
Nothing else this week.
-
Barclays
British bank
- QinetiQ carried out share purchases and arranged for a share buyback execution on the London Stock Exchange.
- Financial institutions provided ratings on multiple companies on July 8, 2026, including Goldman Sachs reiterating Tesla as neutral, Barclays initiating Toast as overweight, and Bank of America rating Nvidia as a buy.
-
UBS
Swiss multinational investment bank and financial services company
Related events
- Exelixis stock trades on the Nasdaq electronic stock exchange.
- Barclays raised its price target for Okta, noting that AI stocks are benefiting from the onshoring trend and Trump-era tariffs.
- Morgan Stanley provided positive research ratings on Exelixis stock, with MarketBeat aggregating the consensus data.
- TD Cowen raised its price target on Exelixis shares on August 30, 2026.
Coverage
Newest first; wire copies grouped- Insider MonkeyExelixis Gains Analyst Confidence as Cancer Studies Advances Exelixis, Inc. (NASDAQ:EXEL) is one of the 13 Best Low Risk High Growth Stocks to Buy. The company advances its studies following a signif